Take Ltd Directors Report

To,

The shareholders of TAKE Limited

The board represents 25th Annual Report along with Standalone and Consolidated Audited Financial Statements for the financial year ended March 31, 2026.

1. Financial Performance:

				(Amt in Lakhs. Except for EPS)
Particulars	Standalone	Consolidated
	FY 2025-26	FY 2024-25	FY 2025-26	FY 2024-25
Revenue from operations	0.00	89.95	5,418.53	0.00
Other Income	661.75	1,297.53	668.73	1,021.90
Total Income	661.75	1,387.48	6,087.26	1,021.90
(-) Total Expenses	374.82	374.54	5,645.64	948.09
Profit/(Loss) before Exceptional Item and Tax	286.93	1,012.94	441.62	73.81
(-) Exceptional Item	0.00	0.00	0.00	0.00
Profit/(Loss) before Tax	286.93	1,012.94	441.62	73.81
Profit/(Loss) for continuing operations	270.91	1,012.94	425.61	73.81
Profit/(Loss) for discontinuing operations	1.00	(7,986.50)	659.30	3,670.20
(-) Tax Expenses	16.02	0.00	16.02	0.00
Profit/(Loss) after Tax	271.91	(6,973.56)	1,084.91	3,746.71
EPS	0.18	(4.71)	0.74	2.53

Opening Balance of Retained earnings

				(Amt in Lakhs.)
Particulars	Standalone	Consolidated
	FY 2025-26	FY 2024-25	FY 2025-26	FY 2024-25
Opening balance of retained earnings	(66,560.64)	(59,587.08)	(66,747.00)	(69,991.12)
Profits for the year	271.91	(6,973.56)	1,088.51	3,746.71
Other comprehensive Income	0.00	0.00	0.00	0.00
Other adjustments	0.00	0.00	(58.20)	(502.60)
(-) Transfer to Statutory Reserves	0.00	0.00	0.00	0.00
Closing balance of retained earnings	(66,288.73)	(66,560.64)	(65,716.70)	(66,747.00)

2. Operations:

The standalone profit before tax for the year under review is Rs. 28,693,000/- as against Rs. 101,294,000/- for the FY 2024-25, whereas the profit after tax for the year under review stands at Rs. 27,191,000/- as against Rs. (697,356,000)/- for the FY 2024-25. The Consolidated profit after tax for the year amounted to Rs. 108,491,000/- as compared to Rs. 374,671,000/- for the FY 2024-25.

3. Dividend:

During the year under review, the board did not declare any dividend.

4. Subsidiary/ Associate /Joint ventures:

During the year under review, the company incorporated a wholly owned companies namely - TAKE Ventures Private Limited.

Details of subsidiaries pursuant to first proviso to sub-section (3) of Section 129 read with Rule 5 of Companies (Accounts) Rules, 2014 are provided in Annexure - 1.

The Company does not have any associate or joint venture.

5. Consolidated Financial Statements:

Consolidated financial statements are applicable to the company for the FY ended 31st March 2026. Consolidated financial statements along with Independent Auditors Report thereon forming part of this Annual Report.

6. Share Capital:

During the year under review, there was no change in the structure of the share capital of the Company.

The details of the authorised, issued, subscribed and paid-up share capital of the Company are as follows:

(a) Authorised Share Capital: 150,00,00,000/- divided into 35,00,00,000 Equity Shares having a face value of 11/- each and 1,50,00,000 Preference Shares having a face value of 110/- each.

(b) Issued, Subscribed and Paid-up Share Capital: 114,79,34,000/- divided into 14,79,34,000 Equity Shares having a face value of 11/- each.

7. Transfer to Reserve:

No amount has been transferred from Profit and Loss to General Reserve for the financial year 2025-26.

8. Change in nature of business:

During the year under review, there has been no change in the nature of business of the Company.

9. Deposits:

There is no instance of acceptance or renewal of deposit pursuant to provisions of section 73 or 74 of the Companies Act read with rules made there under.

10. Particulars of Loans, Guarantees or Investments:

The details of investment made by the company pursuant to preview of section 186 of the Companies Act are forming part of notes annexed to the financial statements. There is no such instance of loan or guarantees to any individual(s).

11. Details of Directors and KMPs:

Pursuant to provisions of section 149 & 203 of the Companies Act and Regulation 06 & 17 of the SEBI Listing Regulations, the company is having 06 (Six) Directors as on date of this Report. The company is also having KMPs as per the applicable provisions of the Companies Act and SEBI Listing Regulations. Details are as follows:

Sr. No. Name	Designation	DIN	Date of Joining
1. Mr. Parmeshvar Dhangare	Chairman & NED	11410125	12/12/2025
2. Mr. Vilas Munis	NED	11533598	11/02/2026
3. Mr. Sunil Patra	MD & CFO	11728362	19/05/2026
4. Ms. Pushpa Joshi	ID	06838093	24/05/2025
5. Mr. Peeyush Sethia	ID	09850692	24/05/2025
6. Mr. Kanwar Nitin Singh	ID	10204543	24/05/2025
7. Ms. Vandana Gupta	CS	-	28/01/2026

Changes during FY 2025-26 are as follows:

Name	Designation	DIN	Date of Joining	Date of Resignation
Ms. Kiran Sharma	ID	00095745	14/02/2023	02/04/2025
Mr. Rangasami Seshadri	ID	00197586	27/09/2022	27/04/2025
Mr. Chandrasekaran Nagarajan	ID	01774322	27/09/2022	01/05/2025
Mr. Ramesh Gopal	ID	00194267	30/06/2022	01/05/2025
Mr. Srinivasan Ramani Harikesanallur	NED	00130277	30/06/2022	01/12/2025
Ms. Cecily Dheepa	NED	07900799	01/05/2025	31/12/2025
Mr. Vedamirtham Venkatesan	ED	00914600	01/05/2025	31/12/2025
Ms. Sonia Bhimrajka	CS	-	27/05/2025	28/01/2026

12. Auditors:

Statutory Auditor:

During the year under review, M/s. Sundar Srini & Sridhar, Chartered Accountants (Firm Registration No. 004201S), resigned as the Statutory Auditors of the Company, resulting in a casual vacancy in the office of the Statutory Auditors.

Pursuant to the provisions of Section 139(8) of the Companies Act, 2013, M/s. Venkat and Rangaa LLP, Chartered Accountants (Firm Registration No. 004597S), were appointed as the Statutory Auditors of the Company to fill the casual vacancy. The appointment was approved by the Members at the Extra-Ordinary General Meeting held on March 7, 2026, to hold office up to the conclusion of the ensuing Annual General Meeting.

Subsequently, M/s. Venkat and Rangaa LLP resigned from the office of the Statutory Auditors on March 25, 2026, due to constraints relating to audit fees. Based on the recommendation of the Audit Committee, the Board of Directors appointed M/s. A. Raghavendra Rao & Associates, Chartered Accountants (Firm Registration No. 003324S), as the Statutory Auditors of the Company to fill the casual vacancy. The appointment was approved by the Members through Postal Ballot on June 16, 2026, and they shall hold office up to the conclusion of the ensuing Annual General Meeting.

The Statutory Auditors have issued a Qualified Opinion on the standalone and consolidated financial statements of the Company for the financial year ended March 31, 2026. The details of the audit qualification, the observations of the Statutory Auditors and the Managements response thereto are set out below:

A. Standalone Financial Statements

Auditors Observation / Details of Audit Qualification:

(i) As stated in the Notes to the Statement, income tax assets (net) appearing in the standalone financial statements of the Company to an extent of Rs. 875.80 Lakhs pertain to various assessment years relating to financial periods ending up to March 31, 2021, which include tax refunds withheld / under process on account of disputes pending before various forums. The Companys management is confident of a favourable outcome on the pending tax litigations and has assessed these amounts as fully recoverable. The contingent liabilities as at 31st March, 2026 in respect of direct tax matters stood at Rs. 108.03 Lakhs. In the absence of final adjudication of the pending appeals, we are unable to confirm the ultimate realisable value of these tax assets, as the timing and quantum of recovery remains contingent upon the outcome of proceedings before appellate authorities. However, we note that the Company has maintained a consistent management assessment regarding recoverability of these balances over the preceding years, and no impairment has been recognised. The consequential impact, if any, on the total assets and profits is not ascertainable at this stage.

Managements Reply:

(a) Tax Assets (Net) to an extent of Rs. 875.80 Lakhs recognised in the standalone financial statements pertain to various assessment years relating to the financial periods ending up to March 31, 2021, are fully recoverable upon completion of the assessment / disposal of the appeals pending in various forums. The refunds are withheld / under process on account of disputes pending before various forums and no impairment is considered necessary and further the Management expects a favourable outcome on the pending tax litigations.

(b) Management has actively engaged consultants to claim refunds where the same is allowed by laws, and the balance amount can be carried forward and set off against any future tax liability that may arise once the business gets revived.

B. Consolidated Financial Statements

Auditors Observation / Details of Audit Qualification:

(i) As stated in the Notes to the Statement, income tax assets appearing in the consolidated financial statements to an extent of Rs. 1,291.90 Lakhs pertain to various assessment years relating to financial periods ending up to March 31, 2026, which are withheld / under process on account of disputes pending before various forums. The management is confident of a favourable outcome on the pending tax litigations and has assessed these amounts as fully recoverable. In the absence of final adjudication of the pending appeals, we are unable to confirm the ultimate realisable value of these tax assets, as the timing and quantum of recovery remains contingent upon the outcome of proceedings before appellate authorities. However, we note that consistent management assessment regarding recoverability of these balances has been maintained over the preceding years, and no impairment has been recognised. The consequential impact, if any, on the total assets and profits of the Group is not ascertainable at this stage.

Managements Reply:

(a) Tax Assets (Net) to an extent of Rs. 1,291.90 Lakhs recognised in the consolidated financial statements pertain to various assessment years relating to financial periods ending up to March 31, 2026. According to the management, these are fully recoverable upon completion of the assessment / disposal of the appeals pending in various forums. The refunds are withheld / under process on account of disputes pending before various forums and no impairment is considered necessary. Management expects a favourable outcome on the pending tax litigations.

(b) Management has actively engaged consultants to claim refunds where the same is allowed by laws, and the balance amount can be carried forward and set off against any future tax liability that may arise once the business gets revived.

Secretarial Auditor:

During the year under review, Mr. Ashok Ajay Kumar Bantia, Practicing Company Secretary (FCS No. 10357, C. P. No. 13620 and Peer Review Certificate No. 3214/2023), resigned as the Secretarial Auditor of the Company with effect from May 29, 2026.

Based on the recommendation of the Audit Committee, the Board of Directors appointed M/s. Hemang Satra & Associates, Practicing Company Secretaries (COP No. 24235 and Peer Review Certificate No. 5684/2024), as the Secretarial Auditor of the Company for a term of five consecutive financial years commencing from Financial Year 2025-26 up to Financial Year 2029-30, subject to the approval of the Members.

M/s. Hemang Satra & Associates have conducted the Secretarial Audit of the Company for the financial year ended March 31, 2026. The Secretarial Audit Report in Form MR-3 and the Annual Secretarial Compliance Report for the financial year ended March 31, 2026 form part of this Annual Report as Annexure 5 and Annexure 4, respectively.

Internal Auditor:

M/s. Tejas Nadkarni & Associates, Chartered Accountants, (FRN: 135197W) were appointed as Internal Auditor of the Company for FY 2025-26.

13. Applicability of Corporate Governance:

The provisions relating to Corporate Governance under Regulations 17 to 27 of the SEBI LODR Regulations are applicable to the Company. Accordingly, a separate Corporate Governance Report containing the requisite disclosures forms part of this Annual Report and is enclosed herewith as Annexure 8.

14. Reporting of Fraud:

During the period under review, there is no instance of fraud that need to be reported under section 143(12) of the Companies Act.

15. Cost Records and Cost Auditors:

The provisions of Section 148 of the Companies Act related to appointment of cost auditor and maintenance of cost records are not applicable to the company.

16. Board Meetings:

The Board met Fifteen (15) times during the Financial Year 2025-26. The necessary quorum was present for all the meetings. The maximum interval between any two meetings did not exceed one hundred and twenty (120) days. The details of the meetings and attendance of the Directors are provided in the Corporate Governance Report forming part of this Annual Report.

17. Committee Meetings:

During the year under review, the Audit Committee, Nomination and Remuneration Committee, Stakeholders Relationship Committee and Risk Management Committee met from time to time to consider and approve matters within their respective terms of reference. Details of the composition of the Committees, meetings held, attendance of the members and other relevant information are provided in the Corporate Governance Report forming part of this Annual Report.

18. Directors Responsibility Statement:

Based on the framework of internal financial controls and compliance systems established and maintained by the Company, the work performed by the Internal, Statutory and Secretarial Auditors and external consultants, including the audit of internal financial controls over financial reporting by the statutory auditors and the reviews performed by management and the Audit Committee, the Board is of the opinion that the Companys internal financial controls were adequate and effective during Financial Year 2025-26.

Pursuant to clause (c) of sub-section (3) and sub-section (5) of Section 134(5) of the Act, the Board of Directors, to the best of its knowledge and ability, confirm that-

(a) in the preparation of the annual accounts, the applicable accounting standards have been followed and that there are no material departures;

(b) they have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent, so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit of the Company for that period;

(c) they have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act, for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

(d) they have prepared the annual accounts on a going concern basis;

(e) they have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and are operating effectively;

(f) They have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

19. Business Responsibility and Sustainability Reporting:

The provisions of submission of Business Responsibility and Sustainability reporting are not applicable to the Company.

20. Management Discussion and Analysis report:

The Management Discussion and Analysis Report (MD&A), for the year under review, as per the provisions of Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, inter alia, capturing your Companys performance, industry trends and other material changes with respect to your Company and its subsidiaries, wherever applicable, is presented separately and forms part of this Annual Report and is enclosed herewith as Annexure 7.

21. Risk Management:

Your Company also has a robust Risk Management Framework in place covering critical areas of operations. This framework is reviewed periodically keeping in mind the business dynamics and external environment and provides the guidelines for managing the various risks across the business. The Risk Management Committee undertakes assessment on risk management procedures from time to time and update the Board on its findings.

22. Internal Financial Control System and their adequacy:

The Company has in place adequate internal financial controls commensurate with the size, scale and nature of its business. The internal financial control framework is designed to provide reasonable assurance regarding the orderly and efficient conduct of business, safeguarding of assets, prevention and detection of frauds and errors, accuracy and completeness of accounting records and the timely preparation of reliable financial information.

The Board believes that the existing internal financial controls are adequate and are operating effectively. During the year under review, no material weakness or significant deficiency in the design or operation of the Companys internal financial controls was reported, which could adversely affect the Companys ability to record, process, summarize and report financial information.

23. Related Party Transactions:

Related Party Transactions entered during the financial year under review were on arms length basis and as per the provisions of section 188 of the Companies Act and Regulation 23 of the SEBI Listing Regulations.

The Company has adopted a Related Party Transactions Policy. The Policy, as approved by the Board, is uploaded on the Companys website. The details of the transactions with Related Parties as per Ind AS 24 are forming part of the financial statements. The disclosure of RPTs as required under Section 134(3)(h) of the Act in Form AOC-2 is forming part of this report enclosed as Annexure 2.

24. Particulars of Employees and Remuneration:

The information pursuant to Section 197(12) of the Companies Act read with Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, details related to the remuneration of Directors, KMPs and Employees are enclosed herewith in Annexure 6.

25. Vigil Mechanism / Whistle Blower Policy:

The Company has implemented a vigil mechanism pursuant to provisions of section 177 (9) & (10) of the Companies Act and Regulation 22 of the SEBI Listing Regulations through the adoption of Whistle blower Policy.

The object is to enable any employees or director to raise genuine concern or report that may constitute the Instances of corporate fraud, unethical conduct, a violation of Central or State laws/rules/regulations and/or any other regulatory or judicial directives. It also provides safeguards against victimization of employees who avail the mechanism and allows direct access to the chairman of the Audit Committee.

26. Policy on prevention, prohibition and redressal of sexual harassment at work place:

The Company has a policy made under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. Your Company has a robust mechanism in place to redress complaints reported under it, if any.

The Company had no complaints of sexual harassment at the beginning of the year and has not received any complaints during the FY. Accordingly, there are no complaints pending at the end of the FY 2025-26.

27. Details on Maternity Benefits:

During the year under review, no maternity benefits have been availed by any of the employee.

28. Corporate Social Responsibility:

During the year under review, since the Company has not crossed the thresholds as specified under section 135 of the Companies Act, 2013, the Company is not required to spend any amount towards Corporate Social Responsibility Activities.

Contents of CSR Policy is also available on Companys website at www.takelimited.com

29. Material order passed by the regulators / courts / Tribunals:

There is no significant material orders passed by the Regulators/Courts/Tribunals which would impact the going concern status of the company and its future operations.

30. Material Changes in the Company and Significant Developments during the Year and up to the Date of this Report :

During the financial year 2025-26 and up to the date of this Report, certain material changes and significant developments have taken place in the Company, details of which are set out below::

1. Shifting of Registered Office

During the financial year under review, the Board of Directors approved the shifting of the Registered Office of the Company from No. 56, Old No. 116, 4th Floor, Ragas Building, Dr. Radhakrishnan Salai, Mylapore, Chennai - 600004, Tamil Nadu to No. B3, No. 9, B Block, Alsa Arcade, 3rd Floor, 2nd Avenue, Anna Nagar East, Chennai - 600102, Tamil Nadu, with effect from 18th December 2025. The Company had duly intimated the Stock Exchanges in this regard under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2. Strategic Expansion into AI-driven Healthcare and Preventive Care

During the year, the Company announced its strategic plan to expand its capabilities in AI-driven healthcare, diagnostics and preventive care, with a focus on developing scalable technology-led healthcare solutions.

On 23rd December 2025, the Company announced its strategic plan to develop an AI-powered Diagnostic & Preventive Care Platform, aimed at enabling early detection, predictive diagnostics and preventive healthcare solutions. The initiative forms part of the Companys long-term growth and value creation roadmap.

On 10th February 2026, the Company announced plans to establish “One Minute Clinic”, an AI-enabled smart diagnostic and preventive healthcare unit, as part of its strategy to develop scalable capabilities in AI- driven preventive healthcare and digital health solutions in India.

On 17th February 2026, the Company further announced its strategic plan to develop a Scalable Unified AI Platform, envisaged as an integrated digital infrastructure and AI marketplace for healthcare providers, including hospitals, diagnostic laboratories, clinical trial organisations and clinics.

On 21st February 2026, the Company announced the integration of advanced artificial intelligence capabilities powered by Anthropics Claude, intended to strengthen its upcoming AI-driven Preventive Healthcare Platform, One Minute Clinic and Unified AI Marketplace.

On 25th March 2026, the Company announced the launch of “Take.Health”, an AI-driven digital health platform designed to provide personalised health intelligence, preventive healthcare insights and continuous health monitoring. The platform is intended to serve both retail and enterprise segments.

3. Entry into Longevity and Anti-Ageing Segment

Subsequent to the financial year-end, on 17th April 2026, the Company announced its strategic entry into the longevity and anti-ageing market in India. The proposed initiative is focused on developing science- backed nutraceuticals, biohacking-focused products and technology-enabled preventive healthcare offerings, leveraging the Companys capabilities in clinical research, life sciences and regulatory processes.

4. Launch of Innovation Fund

Subsequent to the financial year-end, on 6th April 2026, the Company announced the launch of an Innovation Fund with an initial corpus of Rs.50 million (Rs.5 crore) to identify, invest in and support high- potential businesses operating at the convergence of Artificial Intelligence, deep technology and digital health. The initiative is intended to diversify the Companys growth avenues and support long-term value creation.

5. Subsidiary formation

During the financial year under review, the Company incorporated TAKE Ventures Private Limited as a wholly owned subsidiary. The requisite particulars of the subsidiary are provided in Annexure 1 to the Boards Report.

6. Change in Name of the Company

Subsequent to the financial year-end, the Members of the Company, through Postal Ballot, approved the change in name of the Company from “TAKE SOLUTIONS LIMITED” to “TAKE LIMITED”, along with the consequential alterations to the Memorandum of Association and Articles of Association. The resolution was approved by the Members on June 16, 2026. Pursuant thereto, the Company received the Certificate of Incorporation consequent upon change of name from the Ministry of Corporate Affairs on June 25, 2026, and the change in name became effective from June 25, 2026.

7. Adoption of Revised Memorandum of Association

During the year and subsequent to the financial year-end, the Members of the Company, through Postal Ballot, approved the adoption of a revised set of the Memorandum of Association in alignment with the provisions of the Companies Act, 2013. The revised Memorandum, inter alia, provided for merger of the erstwhile Clause III(C) relating to “Other Objects” with Clause III(B) relating to “Objects Incidental or Ancillary to the attainment of the Main Objects”, together with consequential renumbering of the clauses. The resolution was approved by the Members on June 16, 2026.

8. Alteration of Object Clause of the Memorandum of Association

During the year and subsequent to the financial year-end, the Members of the Company, through Postal Ballot, approved the alteration of the Object Clause of the Memorandum of Association by insertion of new objects relating, inter alia, to technology-driven healthcare solutions, artificial intelligence-based systems, digital health platforms, data analytics, preventive and diagnostic healthcare services, pharmaceuticals, biopharmaceuticals, biotechnology products, nutraceuticals, wellness products, clinical research, clinical trials and related healthcare and life sciences activities. The Members also approved consequential incidental and ancillary objects relating to research and development, intellectual property, collaborations, laboratories, manufacturing and distribution infrastructure, data-related activities and other allied matters. The resolution was approved on June 16, 2026.

31. Board / Committee / Individual Directors Performance:

The Board of Directors has carried out an annual evaluation of its own performance, board committees, and individual directors pursuant to the provisions of the Companies Act and SEBI Listing Regulations. In a separate meeting of Independent Directors, performance of Non-Independent directors, the Board as a whole and Chairman of the Company was evaluated, taking into account the views of executive directors and non-executive directors.

Performance evaluation of independent directors was done by the entire Board, excluding the independent director being evaluated.

32. Applicability of Secretarial Standards:

The Company is in compliance with the Secretarial Standards on Meetings of the Board of Directors (SS - 1) and General Meetings (SS - 2) issued by the Institute of Company Secretaries of India.

33. Proceeding under the Insolvency and Bankruptcy Code, 2016

No proceedings are initiated/pending against the Company under the Insolvency and Bankruptcy Code, 2016.

34. Transfer to the Investor Education and Protection Fund:

i. Unclaimed Dividends

Under the provisions of the Companies Act, 2013, dividends that remain unclaimed for a period of seven consecutive years from the date of declaration are required to be transferred to the Investor Education and Protection Fund (“IEPF”) administered by the Central Government:

Financial Year	Amount (in Rs.)	Date of Declaration	Due Date for Transfer to IEPF
2018-19 - 1st Interim Dividend	74,117.40	October 30, 2018	December 06, 2025
2018-19 - 2nd Interim Dividend	94,106.70	February 13, 2019	March 19, 2026
2018-19 - Final Dividend	2,54,817.20	August 08, 2019	September 14, 2026

During the year under review, the Company transferred Rs.74,117.40 pertaining to the 1st Interim Dividend for FY 2018-19 to the IEPF within the prescribed timeline.

The unclaimed dividend pertaining to the 2nd Interim Dividend for FY 2018-19 amounting to Rs.94,106.70 became due for transfer on March 19, 2026 and remains due for transfer to IEPF.

The Final Dividend for FY 2018-19 amounting to Rs.2,54,817.20 is due for transfer on September 14, 2026.

ii. Unclaimed Shares

In terms of Section 124(6) of the Companies Act, 2013 read with Rule 6 of the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, as amended from time to time, shares on which dividend has not been paid or claimed by a shareholder for a period of seven consecutive years or more are required to be credited to the Demat Account of the Investor Education and Protection Fund Authority (“IEPFA”).

Upon transfer of such shares, all benefits accruing on such shares, if any, shall also be credited to the Demat Account of the IEPFA and the voting rights on such shares shall remain frozen until the rightful owner claims the shares. Shares transferred to the Demat Account of the IEPFA can be claimed back by the shareholder by following the prescribed procedure.

Therefore, shareholders are advised to regularly claim the dividends declared by the Company.

iii. Employee Stock Option Scheme:

In accordance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, the excess of the market price of the underlying Equity Shares as of date of the grant over the exercise price of the option, including upfront payments, if any, is to be recognized and amortized on a straight-line basis over the vesting period.

During the current financial year, the Company has not granted any options to its employees under TAKE Limited Employee Stock Option Scheme 2007.

Other Stock option details and the applicable disclosures as stipulated under Regulation 14 of SEBI (Share Based Employee Benefits) Regulations, 2014 with regard to Employees Stock Option Plan of the Company are available on the website of the Company at www.takelimited.com.

iv. Annual Return:

Pursuant to Section 92(3) read with Section 134(3)(a) of the Companies Act, the Annual Return as on 31st March 2026 will be available on the Companys website www.takelimited.com with in stipulated period of time.

v. Conservation of energy, technology absorption, foreign exchange earnings and outgo:

The company has made the necessary disclosures in this Report in terms of section 134 (3)(m) of the Companies Act, 2013 read with rule 8(3) of the Companies (Accounts) Rules, 2014.

The company has always strived to optimize energy consumption. Details of the same is enclosed as Annexure - 3.

vi. Acknowledgements:

The Board wishes to place on record their sincere appreciation for the continued support received from stakeholders, employees, customers, service providers, banks and all other individual directly or indirectly associated with the company.

		For TAKE Limited
	(Formerly known as TAKE Solutions Limited)
	Sd/-	Sd/-
	Mr. Parmeshvar Dhangare	Mr. Sunil Patra
	Chairman	Managing Director & CFO
Date: 03 September 2026	DIN:11410125	DIN:11728362
Place: Chennai
Registered Office:
TAKE Limited
CIN:L72100TN2000PLC046338
Registered Office Address:
No. B3. No.9, B Block, Alsa Arcade, 3rd Floor, 2nd Avenue,
Anna Nagar East, Chennai-600102, Tamil Nadu.
Website: www.takelimited.com
Email id: secretarial@takelimited.com
Mobile: +91 8108618322